ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
96,228.92
1.95%
S&P 500
5,890.09
-0.46%
Dow Jones
43,436.62
0.06%
US Dollar vs Yen
154.107
-0.77%
Brent Oil
73.525
0.94%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. イギリス
  5. LSE

  6. Molecular Partners Ag (0QXX) 銘柄情報

Molecular Partners Ag

Molecular Partners Ag (0QXX)

LSE
25.20
0.00
( 0.00% )
更新日時： 09:00:00
15分遅延

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

主要統計と詳細

通貨
25.20
買値
0.00
売値
0.00
出来高
0.00
0.00 日の範囲 0.00
25.20 52 週間の範囲 25.20
時価総額
916.121M
前日終値
25.20
始値
-
時刻
(O)
最終取引時間
-
財務取引量
-
VWAP
-
平均取引量 (3 か月)
442
発行済株式数
36,354,000
配当利回り
-
PER
-14.78
1 株当たり利益 (EPS)
-1.71
歳入
7.04M
純利益
-61.98M

Molecular Partners Ag について

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
www.molecularpartners.com
本社
Schlieren, Che
設立
-
Molecular Partners Ag is listed in the Pharmaceutical Preparations sector of the ロンドン証券取引所 with ticker 0QXX. The last closing price for Molecular Partners was CHF25.20. Over the last year, Molecular Partners shares have traded in a share price range of CHF 25.20 to CHF 25.20.

Molecular Partners currently has 36,354,000 shares in issue. The market capitalisation of Molecular Partners is CHF916.12 million. Molecular Partners has a price to earnings ratio (PE ratio) of -14.78.

0QXX 最新ニュース

その他のニュース

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024 Preclinical proof-of-concept data supports the...

2024年11月8日
UK Regulatory

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall...

2024年11月6日
UK Regulatory

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going Radio-DARPin Therapy...

2024年11月1日
UK Regulatory

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

Molecular Partners Announces Pricing of $20 Million Underwritten Offering ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art...

2024年10月25日
UK Regulatory

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024 Dose-dependent efficacy observed with...

2024年10月22日
UK Regulatory

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics Under the revised agreement, both companies will co-develop four Radio-DARPin programs;...

2024年10月22日
UK Regulatory

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced...

2024年10月4日
UK Regulatory

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM...

2024年9月27日
UK Regulatory

Molecular Partners Reports H1 2024 Corporate Highlights and Financials

Molecular Partners Reports H1 2024 Corporate Highlights and Financials First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial...

2024年8月27日
UK Regulatory

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of...

2024年6月14日
UK Regulatory
期間 †前日比前日比 %始値高値安値平均出来高VWAP
10025.225.225.250325.2DE
40025.225.225.269025.2DE
120025.225.225.244225.2DE
260025.225.225.240425.2DE
520025.225.225.2165125.2DE
1560025.225.225.21019025.2DE
2600025.225.225.2725525.2DE

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
FARFerro-alloy Resources Limited
5.45p
(131.91%)
30.39M
VELAVela Technologies Plc
0.0075p
(36.36%)
208.9M
ROCRockpool Acquisitions Plc
2.25p
(28.57%)
150k
RCGHRc365 Holding Plc
1.60p
(28.00%)
2.96M
CASPCaspian Sunrise Plc
3.50p
(25.00%)
10.3M
CNNCaledonian Trust Plc
32.50p
(-40.91%)
68.74k
NTOGNostra Terra Oil And Gas Company Plc
0.0235p
(-37.33%)
778.2M
SLFRSlf Realisation Fund Limited
1.02p
(-27.66%)
293.37k
QUIZQuiz Plc
4.02p
(-23.43%)
18.99k
PPSProton Motor Power Systems Plc
0.145p
(-19.44%)
5.46M
NTOGNostra Terra Oil And Gas Company Plc
0.0235p
(-37.33%)
778.2M
NTVONativo Resources Plc
0.0023p
(0.00%)
517.61M
TRPTower Resources Plc
0.028p
(1.82%)
449.25M
HAYDHaydale Graphene Industries Plc
0.115p
(0.00%)
267.69M
MSMNMosman Oil And Gas Limited
0.04p
(0.00%)
227.17M

議論

フィード全体を表示

最近閲覧した銘柄

LSE
0QXX
Molecular Partners
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有